[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Dulguerov P, Allal AS: Nasal and paranasal sinus carcinoma: how can we continue to make progress? Curr Opin Otolaryngol Head Neck Surg; 2006 Apr;14(2):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal and paranasal sinus carcinoma: how can we continue to make progress?
  • PURPOSE OF REVIEW: New developments in the nasal and paranasal sinus cancers are reviewed.
  • RECENT FINDINGS: In addition to woodworking, several risk factors for nasal and paranasal sinus cancers have been identified, most notably smoking.
  • Progress in the differential diagnosis of small round cell nasal and paranasal sinus cancers allows the precise diagnosis of esthesioneuroblastoma.
  • Despite recent improvements, T staging for ethmoid and nasal cavity needs refinement.
  • An association of surgery and radiation therapy remains the best treatment modality.
  • Major developments include endoscopic resection of nasal and paranasal sinus cancers, high-precision radiotherapy techniques such as intensity-modulated radiotherapy, and proton-beam radiotherapy.
  • There is probably no role for chemotherapy in esthesioneuroblastoma.
  • Although chemotherapy is important for aggressive neoplasms, its generalized use for nasal and paranasal sinus cancers awaits the application/development of newer drugs.
  • These drugs might be applied locally since the majority of recurrences remain local.
  • SUMMARY: Progress in the treatment of nasal and paranasal sinus cancers could be achieved through better prevention and the developments of more selective treatments such as endoscopic resection, high-precision radiotherapy, and new chemotherapy drugs.
  • [MeSH-major] Carcinoma. Nasal Cavity / pathology. Nose Neoplasms. Paranasal Sinus Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Analysis

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552261.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


2. Amusa YB, Adediran IA, Akinpelu VO, Famurewa OC, Olateju SO, Adegbehingbe BO, Komolafe EO, Faponle AF, Olasode BJ: Burkitt's lymphoma of the head and neck region in a Nigerian tertiary hospital. West Afr J Med; 2005 Apr-Jun;24(2):139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Burkitt's lymphoma is endemic in Nigeria; it forms about 39% of all childhood cancers.
  • In recent times more of these cases are being seen presenting first to the Ear Nose and Throat clinic.
  • OBJECTIVE: This study is designed to look at the pattern of presentation of head and Neck Burkitt's lymphoma at a Nigerian Tertiary hospital and to evaluate current treatment modality.
  • The proportion of the tumor affecting the Head and neck region were noted.
  • The most common sites that were affected are; the jaw (65.9%), nasal and paranasal sinuses (12.2).
  • Combination Chemotherapy comprising Cyclophosphamide, Oncovin, Methotrexate and Prednisolone (COMP) was the mainstay of management.
  • The treatment outcome was only favorable in 36.6%.
  • Frank drug resistance was found in (2.6%).
  • Some complications of treatment were noted.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Head and Neck Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Nigeria / epidemiology. Retrospective Studies. Surveys and Questionnaires. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] West Afr J Med. 2005 Jul-Sep;24(3):189. Adegbeingbe, OD [corrected to Adegbehingbe, BO]
  • (PMID = 16092315.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


3. Sato H, Murai K, Kanda T, Mimura R, Hiratsuka Y: Association of chromium exposure with multiple primary cancers in the nasal cavity. Auris Nasus Larynx; 2003 Feb;30(1):93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of chromium exposure with multiple primary cancers in the nasal cavity.
  • A 56-year-old man who had worked at a chromate factory for 13 years developed squamous cell carcinoma of the left nasal cavity 11 years after retirement.
  • He received intra-arterial chemotherapy, followed by surgery.
  • Two years later, an adenocarcinoma was identified in the same nasal cavity just above the previous surgical region.
  • Microsatellite markers were examined in the second tumor specimen as a possible factor for carcinogenesis; however, replication errors were not observed in any of four loci (D2S123, D3S1067, TP53, D18S474) tested.
  • The present case seems to have resulted from long-term exposure to chromium and, to our knowledge, is the first reported case with multiple primary cancers in the nasal cavity associated with chromium exposure.
  • [MeSH-major] Adrenal Gland Neoplasms / chemically induced. Carcinoma, Squamous Cell / chemically induced. Chromium / adverse effects. Nasal Cavity / pathology. Neoplasms, Multiple Primary / chemically induced. Nose Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12589859.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0R0008Q3JB / Chromium
  •  go-up   go-down


Advertisement
4. Mondal PK, Pal I, Misra S, Biswas S, Bera SP: Rhabdomyosarcoma of nose, nasopharynx and paranasal sinuses. Indian J Otolaryngol Head Neck Surg; 2009 Dec;61(4):317-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of nose, nasopharynx and paranasal sinuses.
  • Rhabdomyosarcoma is an aggressive malignant soft tissue tumor that arises from primitive striated muscle cells called rhabdomyoblasts.
  • It is the most common soft tissue malignant tumor in children and accounts for about 7-8% of childhood cancers.
  • This article presents six cases of rhabdomyosarcoma involving the nose, nasopharynx and the paranasal sinuses four of which were treated with a combination of radiotherapy and chemotherapy and two were treated with medial maxillectomy combined with chemotherapy and radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1976 Jan;37(1):364-76 [1247965.001]
  • [Cites] J Clin Invest. 1991 Apr;87(4):1133-8 [1849142.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2123-39 [7636557.001]
  • [Cites] Cancer. 1958 Jan-Feb;11(1):181-99 [13500314.001]
  • [Cites] Arch Surg. 1962 May;84:582-8 [13886586.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):337-44 [10888419.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1994 Sep;103(9):699-704 [8085730.001]
  • [Cites] Semin Diagn Pathol. 1994 Feb;11(1):26-38 [8202644.001]
  • (PMID = 23120658.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450072
  • [Keywords] NOTNLM ; Nasopharynx / Nose / Paranasal sinuses / Rhabdomyosarcoma
  •  go-up   go-down


5. LoTempio MM, Wang MB, Sadeghi A: Treatment of advanced oropharyngeal cancers with chemotherapy and radiation. Ear Nose Throat J; 2003 May;82(5):367-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced oropharyngeal cancers with chemotherapy and radiation.
  • We conducted a retrospective chart review of treatment outcomes in 17 adults who had been selected to undergo concomitant chemotherapy and radiation (chemo/XRT) for late-stage oropharyngeal cancers.
  • Nine patients had a primary tumor at the base of the tongue, five had a primary tumor in the tonsillar area, and three had a tumor that affected both sites.
  • Of this group, 15 patients completed one to three cycles of chemo/XRT, and the remaining two died during therapy.
  • At the most recent follow-up, 9 of the 17 patients (52.9%) were documented to still be alive; seven patients had earlier died as a result of their primary tumor or a distant metastasis, and one patient had been lost to follow-up after completing treatment.
  • At study's end, the duration of post-treatment survival ranged from 2 to 36 months (mean: 12.5).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brachytherapy / methods. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Palliative Care / methods
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiation Dosage. Retrospective Studies. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12789762.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Baptista P, Garcia Velloso MJ, Salvinelli F, Casale M: Radioguided surgical strategy in mucosal melanoma of the nasal cavity. Clin Nucl Med; 2008 Jan;33(1):14-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioguided surgical strategy in mucosal melanoma of the nasal cavity.
  • Sinonasal mucosal melanoma (MM), although very rare (<1% of the all MM), is second only to squamous cell carcinoma among cancers of the nasal region and still represents a challenging problem in head and neck cancer.
  • A 60-year-old woman had nasal MM stage I, which was treated with concomitant probe-guided tumor excision and an elective neck dissection after sentinel lymph node biopsy.
  • The radioactivity status of the tumor and lymph nodes were compared with the histopathologic specimen.
  • Surgical margins, sentinel lymph node, and lymphadenectomy were free of tumor.
  • The patient was seen in frequent and regular follow-up and was free of disease without any other treatment (radiotherapy, immunotherapy, or chemotherapy).
  • A multidisciplinary approach and further studies with a longer follow-up are needed to substantiate the accuracy and safety of this strategy in the treatment of an aggressive neoplasm like MM of the head and neck, which still has a very poor prognosis.
  • [MeSH-major] Melanoma / surgery. Nose Neoplasms / surgery
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Female. Gamma Cameras. Humans. Middle Aged. Radiosurgery. Sentinel Lymph Node Biopsy. Technetium Tc 99m Aggregated Albumin. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097249.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid
  •  go-up   go-down


7. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results.
  • OBJECTIVE: To evaluate the oncologic outcomes of patients with sinonasal cancer treated with endoscopic resection.
  • SETTING: Tertiary care academic cancer center.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • The most common site of tumor origin was the nasal cavity (52%), followed by the ethmoid sinuses (28%).
  • However, the T-stage distribution was significantly different between the EEA group and the CEA group.
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • CONCLUSIONS: To the best of our knowledge, this is the largest US series to date of patients with malignant tumors of the sinonasal tract treated with endoscopic resection.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery


8. Pauloski BR: Rehabilitation of dysphagia following head and neck cancer. Phys Med Rehabil Clin N Am; 2008 Nov;19(4):889-928, x
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rehabilitation of dysphagia following head and neck cancer.
  • Patients who have cancers of the oral cavity, pharynx, or larynx may be treated with surgery, radiotherapy, chemotherapy, or a combination of these modalities.
  • Each treatment type may have a negative impact on posttreatment swallowing function; these effects are presented in this article.
  • A number of rehabilitative procedures are available to the clinician to reduce or eliminate swallowing disorders in patients treated for cancer of the head and neck.
  • The various procedures-including postures, maneuvers, modifications to bolus volume and viscosity, range-of-motion exercises, and strengthening exercises-and their efficacy in patients treated for head and neck cancer are discussed.

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Guide to Good Posture.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1993 May;160(5):1005-9 [8470567.001]
  • [Cites] Plast Reconstr Surg. 1993 May;91(6):1027-31 [8479967.001]
  • [Cites] J Speech Hear Res. 1993 Apr;36(2):267-76 [8487519.001]
  • [Cites] J Oral Maxillofac Surg. 1993 Aug;51(8):863-7 [8336223.001]
  • [Cites] Head Neck. 1993 Jul-Aug;15(4):325-34 [8360055.001]
  • [Cites] Head Neck. 1993 Sep-Oct;15(5):419-24 [8407314.001]
  • [Cites] Arch Phys Med Rehabil. 1993 Oct;74(10):1066-70 [8215858.001]
  • [Cites] Head Neck. 2001 Jul;23(7):579-89 [11400247.001]
  • [Cites] Dysphagia. 2001 Summer;16(3):190-5 [11453566.001]
  • [Cites] Dysphagia. 2001 Summer;16(3):216-9 [11453570.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Dec;82(12):1661-5 [11733879.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jan;128(1):54-7 [11784255.001]
  • [Cites] Br J Oral Maxillofac Surg. 2002 Feb;40(1):1-10 [11883962.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1131-41 [11920484.001]
  • [Cites] Laryngorhinootologie. 2002 Mar;81(3):233-42 [11967777.001]
  • [Cites] Plast Reconstr Surg. 2004 Aug;114(2):329-38 [15277796.001]
  • [Cites] Acta Otolaryngol. 2004 Sep;124(7):768-71 [15370557.001]
  • [Cites] Dysphagia. 2004 Spring;19(2):109-19 [15382799.001]
  • [Cites] Laryngoscope. 2004 Nov;114(11):1924-31 [15510015.001]
  • [Cites] Radiology. 1966 Aug;87(2):226-30 [5915425.001]
  • [Cites] Laryngoscope. 1969 May;79(5):887-908 [5770041.001]
  • [Cites] Int Surg. 1969 Jul;52(1):29-40 [5788668.001]
  • [Cites] Laryngoscope. 1975 Aug;85(8):1318-26 [1160463.001]
  • [Cites] Jpn J Clin Oncol. 2005 Nov;35(11):639-44 [16275679.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Dec;262(12):947-52 [16362268.001]
  • [Cites] Head Neck. 2006 Jan;28(1):64-73 [16302193.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Mar;134(3):455-9 [16500444.001]
  • [Cites] Oral Oncol. 2006 Apr;42(4):374-80 [16314138.001]
  • [Cites] Cancer J. 2006 Jan-Feb;12(1):63-8 [16613664.001]
  • [Cites] Oral Oncol. 2006 May;42(5):501-9 [16376135.001]
  • [Cites] Dysphagia. 2000 Winter;15(1):17-8 [10594254.001]
  • [Cites] Head Neck. 2000 Mar;22(2):120-31 [10679899.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):378-83 [10722012.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):384-9 [10722013.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2000 Mar;109(3):320-5 [10737318.001]
  • [Cites] Schweiz Med Wochenschr Suppl. 2000;116:39S-42S [10780069.001]
  • [Cites] Dysphagia. 2000 Summer;15(3):136-41 [10839826.001]
  • [Cites] Dysphagia. 2000 Summer;15(3):142-5 [10839827.001]
  • [Cites] Head Neck. 2000 Jul;22(4):393-7 [10862024.001]
  • [Cites] Br J Oral Maxillofac Surg. 2000 Oct;38(5):513-8 [11010785.001]
  • [Cites] Dysphagia. 2003 Winter;18(1):16-26 [12497192.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):44-9 [12525193.001]
  • [Cites] Curr Treat Options Oncol. 2003 Feb;4(1):27-41 [12525277.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):320-6 [12525525.001]
  • [Cites] Otolaryngol Clin North Am. 2002 Oct;35(5):1067-80 [12587248.001]
  • [Cites] Neurogastroenterol Motil. 2003 Feb;15(1):69-77 [12588471.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):573-9 [12616217.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Mar;128(3):412-8 [12646846.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1693-700 [12655526.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1689-97 [12738722.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):253-62 [12742264.001]
  • [Cites] Head Neck. 2003 Jun;25(6):432-7 [12784234.001]
  • [Cites] Ann Plast Surg. 2003 May;50(5):450-5 [12792531.001]
  • [Cites] Folia Phoniatr Logop. 2003 Jul-Aug;55(4):199-205 [12802092.001]
  • [Cites] Dysphagia. 2003 Spring;18(2):114-25 [12825905.001]
  • [Cites] Dysphagia. 2003 Spring;18(2):135-43 [12825907.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):733-8 [12874074.001]
  • [Cites] Head Neck. 2003 Sep;25(9):711-6 [12953306.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Dec;32(6):593-9 [14636608.001]
  • [Cites] Head Neck. 2004 Apr;26(4):365-72 [15054740.001]
  • [Cites] Cancer. 2004 May 1;100(9 Suppl):2026-46 [15108223.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):187-99 [15062369.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Apr;12(2):82-7 [15167042.001]
  • [Cites] Head Neck. 2004 Jul;26(7):625-36 [15229906.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):831-6 [15262759.001]
  • [Cites] Head Neck Surg. 1987 Jan-Feb;9(3):142-50 [3623944.001]
  • [Cites] Otolaryngol Clin North Am. 1988 Nov;21(4):721-6 [3186256.001]
  • [Cites] J Oral Pathol Med. 1989 Mar;18(3):167-71 [2760855.001]
  • [Cites] Arch Phys Med Rehabil. 1989 Oct;70(10):767-71 [2802957.001]
  • [Cites] J Prosthet Dent. 1990 Mar;63(3):316-20 [2308092.001]
  • [Cites] Am J Physiol. 1991 Mar;260(3 Pt 1):G450-6 [2003609.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 May;117(5):512-5 [1902355.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Am J Surg. 1976 Jan;131(1):30-5 [1247150.001]
  • [Cites] Clin Plast Surg. 1976 Jul;3(3):471-9 [963952.001]
  • [Cites] J Prosthet Dent. 1980 Mar;43(3):313-9 [6986462.001]
  • [Cites] Otolaryngol Head Neck Surg (1979). 1979 Nov-Dec;87(6):779-96 [119201.001]
  • [Cites] Laryngoscope. 1980 Mar;90(3):454-64 [7359966.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1981 Jul-Aug;90(4 Pt 1):331-4 [7271143.001]
  • [Cites] Plast Reconstr Surg. 1982 Mar;69(3):460-9 [7063569.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(2):359-67 [1526875.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2171-80 [1394048.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Nov;118(11):1164-7 [1418894.001]
  • [Cites] J Speech Hear Res. 1992 Dec;35(6):1239-45 [1494269.001]
  • [Cites] Arch Phys Med Rehabil. 1993 Feb;74(2):178-81 [8431103.001]
  • [Cites] Dysphagia. 1993;8(1):11-20 [8436017.001]
  • [Cites] Head Neck. 1993 Mar-Apr;15(2):119-24 [8440612.001]
  • [Cites] Am J Physiol. 1997 Jun;272(6 Pt 1):G1518-22 [9227489.001]
  • [Cites] Ear Nose Throat J. 1997 Jul;76(7):450-3, 456 [9248138.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Aug;123(8):830-6 [9260548.001]
  • [Cites] Head Neck. 1997 Sep;19(6):535-40 [9278762.001]
  • [Cites] Acta Otolaryngol. 1997 Sep;117(5):769-74 [9349879.001]
  • [Cites] Laryngorhinootologie. 1998 Feb;77(2):93-9 [9555703.001]
  • [Cites] Nihon Jibiinkoka Gakkai Kaiho. 1998 Mar;101(3):307-11 [9584470.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 May;118(5):616-24 [9591859.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Jun;124(6):625-30 [9639470.001]
  • [Cites] Oral Oncol. 1998 Mar;34(2):140-6 [9682778.001]
  • [Cites] Acta Otolaryngol. 1998 Sep;118(5):728-31 [9840513.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):455-78 [9922328.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Apr;125(4):410-3 [10208678.001]
  • [Cites] J Speech Hear Res. 1993 Oct;36(5):918-26 [8246480.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Jan;120(1):26-31 [8274252.001]
  • [Cites] Laryngoscope. 1994 Jan;104(1 Pt 1):87-90 [8295463.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Feb;110(2):222-7 [8108157.001]
  • [Cites] Clin Commun Disord. 1993 Fall;3(4):11-20 [8111360.001]
  • [Cites] Plast Reconstr Surg. 1994 Mar;93(3):547-51 [8115509.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):313-22 [8056575.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):419-22 [7977964.001]
  • [Cites] J Speech Hear Res. 1994 Oct;37(5):1041-59 [7823550.001]
  • [Cites] J Speech Hear Res. 1994 Oct;37(5):965-74 [7823564.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Sep;121(9):959-64 [7646863.001]
  • [Cites] Laryngoscope. 1995 Oct;105(10):1104-10 [7564843.001]
  • [Cites] Plast Reconstr Surg. 1995 Oct;96(5):1081-9; discussion 1090-1 [7568483.001]
  • [Cites] J Craniomaxillofac Surg. 1995 Aug;23(4):243-9 [7560111.001]
  • [Cites] Dysphagia. 1996 Winter;11(1):2-8 [8556873.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1996 Feb;105(2):123-31 [8659933.001]
  • [Cites] J Otolaryngol. 1996 Apr;25(2):75-81 [8683656.001]
  • [Cites] J Oral Maxillofac Surg. 1996 Jun;54(6):664-9; discussion 669-70 [8648469.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Dysphagia. 1996 Summer;11(3):187-90 [8755463.001]
  • [Cites] Dysphagia. 1996 Summer;11(3):198-206 [8755466.001]
  • [Cites] Laryngoscope. 1996 Sep;106(9 Pt 1):1157-66 [8822723.001]
  • [Cites] Dysphagia. 1996 Fall;11(4):225-33 [8870348.001]
  • [Cites] Nihon Jibiinkoka Gakkai Kaiho. 1997 Feb;100(2):220-6 [9071122.001]
  • [Cites] Oncology (Williston Park). 1997 May;11(5):651-6, 659; discussion 659, 663-4 [9159792.001]
  • [Cites] Laryngorhinootologie. 1997 Apr;76(4):229-34 [9264597.001]
  • [Cites] Clin Radiol. 2000 Oct;55(10):775-81 [11052879.001]
  • [Cites] Semin Speech Lang. 2000;21(4):293-309 [11085254.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1961-9 [11283128.001]
  • [Cites] Dysphagia. 2001 Spring;16(2):119-22 [11305221.001]
  • [Cites] Respir Care. 2001 May;46(5):466-74 [11309186.001]
  • [Cites] Cancer. 2001 May 1;91(9):1785-90 [11335904.001]
  • [Cites] J Speech Lang Hear Res. 2000 Aug;43(4):1011-23 [11386468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] Head Neck. 2001 Apr;23(4):317-21 [11400234.001]
  • [Cites] Nihon Jibiinkoka Gakkai Kaiho. 1999 Mar;102(3):311-6 [10226467.001]
  • [Cites] Folia Phoniatr Logop. 1999 Jul-Oct;51(4-5):199-212 [10450026.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1314-21 [11984518.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Int J Cancer. 2001;96 Suppl:61-70 [11992387.001]
  • [Cites] Curr Atheroscler Rep. 2002 Jul;4(4):311-8 [12052283.001]
  • [Cites] Dysphagia. 2002 Summer;17(3):197-201 [12140645.001]
  • [Cites] Folia Phoniatr Logop. 2002 Jul-Aug;54(4):171-6 [12169803.001]
  • [Cites] Ann Plast Surg. 2002 Dec;49(6):612-6 [12461444.001]
  • [Cites] Laryngoscope. 2005 Jul;115(7):1266-71 [15995519.001]
  • [Cites] Arch Phys Med Rehabil. 2005 Jul;86(7):1416-9 [16003674.001]
  • [Cites] Head Neck. 2005 Sep;27(9):757-61 [16086412.001]
  • [Cites] Curr Probl Cancer. 2005 Jul-Aug;29(4):201-14 [16143168.001]
  • [Cites] Dysphagia. 2005 Spring;20(2):149-56 [16172825.001]
  • [Cites] Clin Otolaryngol. 2005 Oct;30(5):428-37 [16232247.001]
  • [Cites] Rays. 2005 Apr-Jun;30(2):137-44 [16294906.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):577-87 [10524409.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1964 Dec;73:1062-81 [14239526.001]
  • [Cites] Head Neck. 2004 Dec;26(12):1038-44 [15459922.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):11-20, vii [15649495.001]
  • [Cites] Curr Opin Oncol. 2005 May;17(3):241-8 [15818168.001]
  • [Cites] Cancer. 2005 May 15;103(10):2073-81 [15816049.001]
  • [Cites] J Otolaryngol. 2004 Dec;33(6):356-9 [15971650.001]
  • [Cites] Head Neck. 2007 Jul;29(7):632-7 [17230558.001]
  • [Cites] Head Neck. 2007 Jul;29(7):638-47 [17274054.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Jun;133(6):564-71 [17576907.001]
  • [Cites] Dysphagia. 2007 Jul;22(3):165-73 [17318684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98 [17560051.001]
  • [Cites] Lung. 2007 Sep-Oct;185(5):243-8 [17661135.001]
  • [Cites] Dysphagia. 2007 Oct;22(4):312-25 [17694407.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):74-82 [17673322.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):64-73 [17714815.001]
  • [Cites] Srp Arh Celok Lek. 1994 Nov-Dec;122(11-12):319-22 [17974407.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2007 Nov;116(11):837-41 [18074669.001]
  • [Cites] Head Neck. 2008 Feb;30(2):148-58 [17786992.001]
  • [Cites] J Speech Lang Hear Res. 2008 Feb;51(1):173-83 [18230864.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Jun;134(6):916-22 [16730530.001]
  • [Cites] Laryngoscope. 2006 Jun;116(6):883-6 [16735913.001]
  • [Cites] Folia Med (Plovdiv). 2005;47(3-4):20-3 [16761389.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Jul;35(7):581-7 [16697144.001]
  • [Cites] Dysphagia. 2006 Jan;21(1):56-60 [16544086.001]
  • [Cites] Dysphagia. 2006 Jan;21(1):66-74 [16544094.001]
  • [Cites] Dysphagia. 2006 Apr;21(2):116-20 [16685468.001]
  • [Cites] J Dent Res. 2006 Aug;85(8):690-700 [16861284.001]
  • [Cites] Head Neck. 2006 Aug;28(8):663-70 [16783832.001]
  • [Cites] Head Neck. 2006 Sep;28(9):808-12 [16732601.001]
  • [Cites] Acta Radiol. 2006 Sep;47(7):628-33 [16950694.001]
  • [Cites] Cancer J. 2006 Sep-Oct;12(5):348-54 [17034671.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Nov;135(5):754-7 [17071307.001]
  • [Cites] J Appl Physiol (1985). 2006 Dec;101(6):1657-63 [16873602.001]
  • [Cites] Head Neck. 2006 Dec;28(12):1069-76 [16823874.001]
  • [Cites] Am J Otolaryngol. 2007 Jan-Feb;28(1):3-8 [17162122.001]
  • [Cites] Laryngoscope. 2007 Jan;117(1):142-6 [17202944.001]
  • [Cites] Head Neck. 2007 Feb;29(2):137-42 [17111432.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2007;69(2):116-20 [17159375.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2007 Jan;116(1):36-44 [17305276.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):976-81 [17234360.001]
  • [Cites] J Support Oncol. 2007 Feb;5(2 Suppl 1):13-21 [17366929.001]
  • [Cites] Oral Oncol. 2007 Apr;43(4):389-94 [16979926.001]
  • [Cites] Neurol Res. 2007 Jan;29(1):9-15 [17427268.001]
  • [Cites] Oral Oncol. 2007 May;43(5):431-9 [17112771.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jun;65(6):1077-83 [17517289.001]
  • [Cites] Clin Plast Surg. 1982 Jan;9(1):21-6 [7094519.001]
  • [Cites] Arch Otolaryngol. 1983 Mar;109(3):175-7 [6337590.001]
  • [Cites] AJR Am J Roentgenol. 1983 Aug;141(2):335-9 [6603130.001]
  • [Cites] Br J Plast Surg. 1984 Oct;37(4):486-92 [6498385.001]
  • [Cites] Clin Plast Surg. 1985 Jul;12(3):453-61 [3893848.001]
  • [Cites] Head Neck Surg. 1985 Sep-Oct;8(1):9-20 [4066369.001]
  • [Cites] Plast Reconstr Surg. 1986 Jul;78(1):1-8 [3725941.001]
  • [Cites] J Prosthet Dent. 1987 Jun;57(6):715-9 [3473231.001]
  • [Cites] Head Neck Surg. 1986 Sep-Oct;9(1):3-12 [3623931.001]
  • [Cites] Head Neck. 1991 Jul-Aug;13(4):334-9 [1907953.001]
  • [Cites] Laryngoscope. 1991 Sep;101(9):935-50 [1886442.001]
  • [Cites] Dysphagia. 1991;6(2):120-2 [1935259.001]
  • [Cites] J Oral Rehabil. 1991 Nov;18(6):483-9 [1762020.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Feb;101(2 Pt 1):138-41 [1739258.001]
  • [Cites] J Speech Hear Res. 1991 Dec;34(6):1257-68 [1787707.001]
  • [Cites] Eur J Cancer. 1992;28(2-3):457-62 [1591063.001]
  • [Cites] Head Neck. 1997 Jul;19(4):287-96 [9213107.001]
  • (PMID = 18940647.001).
  • [ISSN] 1047-9651
  • [Journal-full-title] Physical medicine and rehabilitation clinics of North America
  • [ISO-abbreviation] Phys Med Rehabil Clin N Am
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / R01DC007659; United States / NIDCD NIH HHS / DC / R01 DC007659-03; United States / NCI NIH HHS / CA / R01CA95576; United States / NCI NIH HHS / CA / CA095576-05; United States / NIDCD NIH HHS / DC / R01 DC007659; United States / NIDCD NIH HHS / DC / DC007659-03; United States / NCI NIH HHS / CA / R01 CA095576; United States / NCI NIH HHS / CA / R01 CA095576-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS79126; NLM/ PMC2593402
  •  go-up   go-down


9. Jimbo H, Kamata S, Miura K, Asamoto S, Tada S, Endo T, Masubuchi T, Nakamura N, Fushimi C: Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases. Neurol Med Chir (Tokyo); 2010 Jan;50(1):20-6; discussion 26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases.
  • Cancers of the paranasal sinuses and nasal cavity are the most common malignant tumors of the anterior and anterolateral skull base.
  • The treatment of these tumors affecting the skull base is complex due to the significant anatomical features.
  • Using a combination of adjuvant radiation and chemotherapy, we have achieved a 2-year disease-free survival rate of 90% in these cases.
  • We believe that the optimal management of such malignant tumors involves a multimodal and multidisciplinary team approach.
  • Here we present our recent institutional experience and treatment policy employed during the past 3 years.
  • [MeSH-major] Neurosurgical Procedures / methods. Nose Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery. Skull Base / pathology. Skull Base / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Cranial Fossa, Middle / anatomy & histology. Cranial Fossa, Middle / pathology. Cranial Fossa, Middle / surgery. Drug Therapy / methods. Drug Therapy / statistics & numerical data. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Orbit / anatomy & histology. Orbit / pathology. Orbit / surgery. Osteotomy / contraindications. Osteotomy / methods. Paranasal Sinuses / anatomy & histology. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Patient Care Team. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Postoperative Complications / prevention & control. Radiotherapy, Adjuvant / methods. Radiotherapy, Adjuvant / statistics & numerical data. Reconstructive Surgical Procedures / methods. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098020.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Oral pilocarpine: new preparation. Xerostomia after radiation therapy: moderately effective but costly. Prescrire Int; 2002 Aug;11(60):99-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral pilocarpine: new preparation. Xerostomia after radiation therapy: moderately effective but costly.
  • (1) Dry mouth (xerostomia) is a frequent complication of radiation therapy for cancers of the ear nose and throat.
  • Local measures such as saliva substitutes and anetholtrithione are either moderately effective, inadequately evaluated or little better than placebo. (2) Marketing authorization has been granted in France for an oral formulation of pilocarpine, an old parasympathomimetic agent, in the treatment of radiotherapy-induced xerostomia. (3) According to the results of two double-blind trials, pilocarpine (15-30 mg/day) improves symptoms in about 50 % of patients, compared to improvement in 25% of patients taking placebo.
  • The drug is slow to take effect and has little impact on daily life.
  • Pilocarpine must therefore be used with caution in patients with asthma, cardiac arrhythmia, iridocyclitis, and closed-angle glaucoma. (5) In France, this pilocarpine formulation costs 18 times more than a preparation of pilocarpine 2% eye drops used orally (off licence). (6) In practice, patients needing symptomatic treatment of xerostomia after radiotherapy may benefit from oral pilocarpine but, given its limited efficacy and its adverse effects, other local treatments should be tried first.
  • [MeSH-major] Pilocarpine / therapeutic use. Xerostomia / drug therapy
  • [MeSH-minor] Administration, Oral. Drug Costs. France. Humans. Muscarinic Agonists / administration & dosage. Muscarinic Agonists / adverse effects. Muscarinic Agonists / economics. Muscarinic Agonists / therapeutic use. Radiotherapy / adverse effects. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dry Mouth.
  • Hazardous Substances Data Bank. PILOCARPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12199276.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Muscarinic Agonists; 01MI4Q9DI3 / Pilocarpine
  •  go-up   go-down


11. Jang NY, Wu HG, Park CI, Heo DS, Kim DW, Lee SH, Rhee CS: Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity. Jpn J Clin Oncol; 2010 Jun;40(6):542-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity.
  • OBJECTIVE: To evaluate the efficacy and toxicity of definitive radiotherapy with or without chemotherapy for T3-4 squamous cell carcinoma of maxillary sinus and nasal cavity.
  • METHODS: Forty-two patients with T3-4N0 squamous cell carcinoma of maxillary sinus (n = 30) and nasal cavity (n = 12) received definitive radiotherapy.
  • Chemotherapy was used in 34 patients and elective neck irradiation was not used.
  • RESULTS: The 5-year overall survival/local control rates were 34%/29% for maxillary sinus cancer and 50%/52% for nasal cavity cancer.
  • For maxillary sinus cancers, a performance status of Eastern Cooperative Oncology Group >or=2 (P = 0.012), biologically equivalent dose <68 Gy (P = 0.011) and no use of chemotherapy (P = 0.037) were significant worse predictors for overall survival on log-rank analysis.
  • Biologically equivalent dose <68 Gy was independently associated with poor local control (hazard ratio, 3.32; 95% confidence interval, 1.38-7.97; P = 0.007) and overall survival (hazard ratio, 2.94; 95% confidence interval, 1.23-7.01; P = 0.015).
  • Regional recurrence occurred in only 1 of 30 patients with maxillary sinus cancer and 4 of 12 patients with nasal cavity.
  • CONCLUSIONS: The treatment outcome was poor and local control was a major problem.
  • High radiation dose, effective chemotherapy and elective neck irradiation for advanced nasal cavity cancers may improve disease control.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Maxillary Sinus Neoplasms / radiotherapy. Nasal Cavity. Nose Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Palliative Care. Prognosis. Radiation Injuries. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185459.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


12. Knight V, Kleinerman ES, Waldrep JC, Giovanella BC, Gilbert BE, Koshkina NV: 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann N Y Acad Sci; 2000;922:151-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice.
  • The purpose of this study was to test the anticancer properties of the water-insoluble derivative of camptothecin, 9-nitrocamptothecin (9NC), administered in a liposome formulation (L-9NC) in aerosol to mice with subcutaneous xenografts of three human cancers and in mice with murine melanoma and human osteosarcoma pulmonary metastases.
  • The drug was formulated with dilauroylphosphatidylcholine and nebulized in particle sizes of 1.2-1.6 microns mass median aerodynamic diameter and a geometric standard deviation of 2.0.
  • The aerosol was generated with the nebulizer flowing at 10 l/min and delivered to mice in sealed plastic cages or in a nose-only exposure chamber.
  • With subcutaneous tumors, growth was greatly inhibited or tumors were undetectable after several weeks of treatment.
  • We also showed that oral dosage with L-9NC had no detectable effect on cancer growth, and thus the benefit from aerosol treatment was due to pulmonary deposition and not the larger fraction of drug deposited in the nose of mice during aerosol treatment which is promptly swallowed.
  • Intramuscular L-9NC in slightly larger doses than given in the aerosol had detectable anticancer activity, but it was significantly less than in mice receiving the drug by aerosol.
  • With metastatic pulmonary cancers, treated animals showed highly significantly less cancer growth than control animals.
  • L-9NC aerosol showed a major therapeutic benefit in the treatment of subcutaneous human cancer xenografts in nude mice, suggesting that cancers at systemic sites might be responsive to this treatment.
  • In addition, the strong anticancer effect of L-9NC aerosol on pulmonary metastases offers a therapeutic approach for treatment of pulmonary cancers.
  • Thus, L-9NC aerosol may have applicability in the treatment of cancers throughout the body.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Camptothecin / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Aerosols. Animals. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Colonic Neoplasms / drug therapy. Drug Carriers. Female. Humans. Liposomes. Mammary Neoplasms, Experimental / drug therapy. Melanoma, Experimental / drug therapy. Melanoma, Experimental / secondary. Mice. Mice, Inbred C57BL. Mice, Nude. Microscopy, Electron. Osteosarcoma / drug therapy. Osteosarcoma / secondary. Particle Size. Phosphatidylcholines / administration & dosage. Phosphatidylcholines / chemistry. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193890.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 42992; United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Liposomes; 0 / Phosphatidylcholines; 18285-71-7 / 1,2-dilauroylphosphatidylcholine; H19C446XXB / rubitecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


13. Llorente JL, Pérez-Escuredo J, Alvarez-Marcos C, Suárez C, Hermsen M: Genetic and clinical aspects of wood dust related intestinal-type sinonasal adenocarcinoma: a review. Eur Arch Otorhinolaryngol; 2009 Jan;266(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and clinical aspects of wood dust related intestinal-type sinonasal adenocarcinoma: a review.
  • Intestinal-type sinonasal adenocarcinoma (ITAC) is a rare epithelial cancer of the nasal cavities and paranasal sinuses.
  • Standard therapeutic modalities include surgery followed by radiotherapy in advanced stages, sometimes with chemotherapy treatment.
  • The molecular genetic mechanisms underlying the development and progression of this tumor is not understood.
  • This review aims to describe the clinico-pathological characteristics of this relatively unknown tumor and to summarize the knowledge on genetic and chromosomal analyses up to the present time.
  • [MeSH-major] Adenocarcinoma / etiology. Neoplasm Recurrence, Local / pathology. Occupational Exposure / adverse effects. Paranasal Sinus Neoplasms / etiology. Wood / adverse effects
  • [MeSH-minor] Dust. Female. Genetic Predisposition to Disease / epidemiology. Humans. Immunohistochemistry. Male. Molecular Biology. Neoplasm Staging. Prognosis. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Apoptosis. 2004 Mar;9(2):123-30 [15004509.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):335-41 [14716769.001]
  • [Cites] Surg Neurol. 1994 Aug;42(2):98-104 [8091301.001]
  • [Cites] Arch Otorhinolaryngol. 1988;245(1):1-15 [2839136.001]
  • [Cites] J Otolaryngol. 1993 Apr;22(2):86-90 [8515523.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1345-57 [15001537.001]
  • [Cites] Head Neck. 1998 May;20(3):224-31 [9570628.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4901-6 [15611505.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10 ):1080-3 [15452164.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):315-9 [15492756.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):740-2 [10699958.001]
  • [Cites] Acta Otolaryngol Suppl. 1998;535:1-16 [9725790.001]
  • [Cites] Mod Pathol. 1995 May;8(4):421-6 [7567943.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1109-19 [12360473.001]
  • [Cites] Br Med J. 1968 Jun 8;2(5605):587-96 [5654629.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):141-6 [11177030.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Jul;135(1):135-9 [16815198.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):99-106 [15068833.001]
  • [Cites] Head Neck. 2004 Feb;26(2):136-44 [14762882.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):197-201 [11936913.001]
  • [Cites] Acta Otorhinolaryngol Belg. 1996;50(1):19-24 [8669267.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):765-8 [8663951.001]
  • [Cites] Cell. 2004 Sep 17;118(6):671-4 [15369667.001]
  • [Cites] Am J Surg Pathol. 1986 Mar;10 (3):192-202 [3953940.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4817-25 [15256451.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1513-9 [15860506.001]
  • [Cites] Acta Otolaryngol. 1986 May-Jun;101(5-6):501-8 [3727983.001]
  • [Cites] Acta Otorrinolaringol Esp. 2008 May;59(5):235-8 [18501159.001]
  • [Cites] Acta Otorrinolaringol Esp. 2004 Jan;55(1):27-33 [15108619.001]
  • [Cites] Laryngoscope. 2008 Mar;118(3):437-43 [18176354.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2154-9 [18186150.001]
  • [Cites] Am J Surg Pathol. 1982 Dec;6(8):803-9 [7168462.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):255-64 [10421261.001]
  • [Cites] Head Neck. 2006 Oct;28(10 ):909-15 [16906516.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] J Pathol. 2005 Oct;207(2):207-15 [16041693.001]
  • [Cites] Mod Pathol. 1996 Mar;9(3):199-204 [8685214.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):196-203 [12673679.001]
  • [Cites] Am J Epidemiol. 1994 Aug 15;140(4):340-9 [8059769.001]
  • [Cites] Acta Otolaryngol. 1984 Sep-Oct;98(3-4):321-34 [6496064.001]
  • [Cites] Cancer Lett. 1998 Apr 10;126(1):59-65 [9563649.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):482-8 [6733678.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1988 Sep;114(9):996-9 [3408582.001]
  • (PMID = 18560862.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dust
  • [Number-of-references] 47
  •  go-up   go-down


14. Biel M: Advances in photodynamic therapy for the treatment of head and neck cancers. Lasers Surg Med; 2006 Jun;38(5):349-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in photodynamic therapy for the treatment of head and neck cancers.
  • Photodynamic therapy (PDT) is an FDA-approved minimally invasive medical treatment modality that utilizes light in the presence of oxygen to activate photosensitizing agents that are relatively selectively concentrated in abnormal or neoplastic cells resulting in cell death.
  • At the present time, PDT has been approved for clinical treatment in the United States, European Union, Canada, Russia, and Japan.
  • In the United States, US Food and Drug administration approval has been given for the use of PDT in the treatment of Barrett's esophagus, obstructing esophageal carcinoma and early and obstructing tracheobronchial carcinoma using the photosensitizer Photofrin; actinic keratosis using the photosensitizer Levulan (aminolevulinic acid); and macular degeneration using the photosensitizer BPD.
  • In the EU the above noted indications have also been approved in addition to the treatment of early head and neck cancers and palliative treatment of head and neck cancer using the photosensitizer Foscan; and treatment of basal and squamous cell skin cancers using the photosensitizer Metvix.
  • [MeSH-major] Dihematoporphyrin Ether / therapeutic use. Head and Neck Neoplasms / therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ambulatory Care. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. Male. Melanoma / therapy. Middle Aged. Minnesota / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Papilloma / therapy. Retrospective Studies. Sarcoma, Kaposi / therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788923.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


15. Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D: B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol; 2009 Aug;34(4):328-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: This study aimed to evaluate the response of refractory Wegener's granulomatosis affecting the ear, nose and throat and granulomatous eye disease to B-cell depletion with rituximab.
  • MAIN OUTCOME MEASURES: Demographic and follow-up data at five time points were recorded.
  • Total Birmingham Vasculitis Assessment score decreased after rituximab at all time points (P < 0.001).
  • Four of five patients with retro-orbital involvement responded well to treatment.
  • Two patients were considered secondary failures requiring alternative therapy after an initial response.
  • Adverse events included four major chest infections, two cancers and six infusion reactions.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. B-Lymphocytes / drug effects. Granulomatosis with Polyangiitis / drug therapy. Immunologic Factors / therapeutic use. Lymphocyte Depletion / methods. Otorhinolaryngologic Diseases / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Antineutrophil Cytoplasmic / blood. Antibodies, Monoclonal, Murine-Derived. Cohort Studies. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Prednisolone / adverse effects. Prednisolone / therapeutic use. Recurrence. Retreatment. Rituximab. Young Adult

  • Genetic Alliance. consumer health - Wegener's granulomatosis.
  • MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Otolaryngol. 2009 Dec;34(6):581-2 [20070778.001]
  • (PMID = 19673980.001).
  • [ISSN] 1749-4486
  • [Journal-full-title] Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • [ISO-abbreviation] Clin Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


16. Hu WH, Xie FY, Fang SH, Jiao JJ, Yan C, Peng WJ, Fu XY, Zhang F: [Cancer of the nasal cavity]. Zhonghua Zhong Liu Za Zhi; 2005 Feb;27(2):117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of the nasal cavity].
  • OBJECTIVE: To analyze the factors affecting prognosis of patients with nasal carcinoma.
  • The 5-year survival rate was 55.8% in squamous-cell carcinoma, 44.0% in adenocarcinoma, 59.7% in undifferentiated carcinoma, 76.3% in adenoid cystic carcinoma, 71.4% in mucoepidermoid carcinoma, 25.0% in rhabdomyosarcoma, 26.7% in malignant melanoma, 50.0% in neuroblastoma (P > 0.05).
  • The 5-year survival rate was 73.8% in patients whose cancer completely disappeared after treatment.
  • It was 41.6% in patients whose cancer incompletely disappeared, and 34.3% in patients whose cancer remained refractory (P < 0.01).
  • That with chemotherapy only was 25.0% whereas that of patients treated with combination treatment was 61.8% (P > 0.05).
  • CONCLUSION: Clinical stage, immediate therapeutic response and involvement of sphenoidal or maxillary sinus; but not the pathologic type, the presence of cervical metastasis nor the method of treatment, are the factors affecting the prognosis of patients with nasal carcinoma.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / mortality. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946555.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


17. Bradley PJ, Jones NS, Robertson I: Diagnosis and management of esthesioneuroblastoma. Curr Opin Otolaryngol Head Neck Surg; 2003 Apr;11(2):112-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of esthesioneuroblastoma.
  • Esthesioneuroblastoma is an uncommon malignant neoplasm of the nasal vault that in the past was considered benign or low-grade malignant.
  • Large tumors should be considered for preoperative chemotherapy and postoperative radiotherapy.
  • Local tumor recurrence is not uncommon and is generally related to the attention to local anatomic dissection.
  • Distant metastases may present at any time during the course of the disease, generally within 36 months, and may respond to local radiotherapy or systemic chemotherapy.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / diagnosis. Esthesioneuroblastoma, Olfactory / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures / methods. Prognosis. Radiotherapy / methods. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14515089.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 58
  •  go-up   go-down


18. Daele JJ, Vander Poorten V, Rombaux P, Hamoir M: Cancer of the nasal vestibule, nasal cavity and paranasal sinuses. B-ENT; 2005;Suppl 1:87-94; quiz 95-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the nasal vestibule, nasal cavity and paranasal sinuses.
  • The usual clinical presentation of sinonasal tumours includes symptoms that are indistinguishable from inflammatory sinus disease, namely nasal airway obstruction, pain, and epistaxis.
  • Computed tomography is the most reliable and informative imaging tool for evaluating the cancers of the paranasal sinuses.
  • Magnetic resonance imaging is essential for tumour mapping because of the excellent tissue characterisation and the possibility of differentiating between neoplasms and retained secretions.
  • The response of sinonasal tract tumours to radiation therapy varies with the stage and histology of the tumour.
  • Management of these tumours requires a multimodal approach, involving surgery, radiation therapy and, increasingly in recent years, chemotherapy.
  • [MeSH-major] Nasal Cavity / pathology. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363270.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 49
  •  go-up   go-down


19. Karaman E, Duman C, Mercan H, Ozaras R, Cansız H: Relapsing deep neck infection may indicate a coexisting esophagus cancer. Kulak Burun Bogaz Ihtis Derg; 2009 Mar-Apr;19(2):103-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsing deep neck infection may indicate a coexisting esophagus cancer.
  • Primary head and neck cancers may present initially with neck abscesses or deep neck infections.
  • This presentation leads to delay of the diagnosis of underlying cancer.
  • Head and neck cancers which present with deep neck infection initially have rarely been described.
  • [MeSH-major] Abscess / etiology. Carcinoma, Squamous Cell / diagnosis. Esophageal Neoplasms / diagnosis. Infection / diagnosis
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Cephalosporins / therapeutic use. Cervical Vertebrae / radiography. Female. Humans. Klebsiella Infections / diagnosis. Klebsiella Infections / drug therapy. Middle Aged. Necrosis. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Abscess.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19796009.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Cephalosporins
  •  go-up   go-down


20. Wormald R, Sheahan P, Timon C: A case of head and neck cancer metastasizing to the axillary lymph nodes. Ear Nose Throat J; 2010 Aug;89(8):E24-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of head and neck cancer metastasizing to the axillary lymph nodes.
  • Metastases of head and neck cancers to the axillary lymph nodes are rare.
  • Positron-emission tomography/computed tomography demonstrated high F18-fluorodeoxyglucose uptake in the neck and also in the right axilla.
  • The patient was subsequently treated with chemoradiotherapy, but 6 months later he developed an SCC in the lung.
  • The lung lesion was also treated with chemotherapy, but the patient died 5 months later.
  • Our case is unique among similar cases in that our patient had not undergone any previous treatment of the neck primary.
  • [MeSH-major] Axilla. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Drug Therapy. Head and Neck Neoplasms / pathology. Lymph Nodes / surgery. Neck Dissection. Radiotherapy
  • [MeSH-minor] Aged. Biopsy, Needle. Combined Modality Therapy. Fatal Outcome. Humans. Lymphatic Metastasis / pathology. Male. Positron-Emission Tomography


21. Chou RH, Wilder RB, Wong MS, Forster KM: Recent advances in radiotherapy for head and neck cancers. Ear Nose Throat J; 2001 Oct;80(10):704-7, 711-4, 716 passim
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in radiotherapy for head and neck cancers.
  • Advancements in surgery have made it possible to resect cancers that had previously been regarded as incurable.
  • Similarly, new developments in radiation oncology have helped improve the outlook for patients with locally advanced or recurrent head and neck cancers.
  • These recent developments have allowed radiation oncologists to escalate the dose of radiation delivered to tumors while minimizing the dose delivered to surrounding normal tissue.
  • Additionally, more continues to be learned about the optimum delivery of chemotherapy.
  • This article provides an update on the status of these new developments in the treatment of head and neck cancers.
  • [MeSH-minor] Combined Modality Therapy. Dose Fractionation. Humans. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods. Radiotherapy, High-Energy / adverse effects. Radiotherapy, High-Energy / methods. Survival Rate

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11605568.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


22. Garandawa HI, Ahmad BM, Nggada HA: Nasopharyngeal cancer in North--Eastern Nigeria: clinical trends. Niger J Clin Pract; 2009 Dec;12(4):379-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal cancer in North--Eastern Nigeria: clinical trends.
  • BACKGROUND: Nasopharyngeal cancer is the malignancy of the posterior aspect of the nose called Nasopharynx.
  • AIM: To determine prevalence, clinical trends and histopathological types of Nasopharyngeal cancer in Maiduguri, North Eastern Nigeria.
  • PATIENTS AND METHOD: Fifteen year retrospective evaluation of patient's case notes and cancer registry records of 40 patients with histologically confirmed nasopharyngeal cancer between 1991-2005.
  • RESULTS: Nasopharyngeal cancers constituted 35.1% of all malignancies of ear, nose, throat during the study period.
  • The M:F was 2.1-1, the mean age was 39(+/- 16.5) years and a peak age group and its occurrence of 40-49 years.
  • The commonest histological type was squamous cell carcinoma(92.5%).
  • Patients who received chemotherapy in addition to radiotherapy and higher symptom free period.
  • CONCLUSION: Cancer is a difficult disease to diagnose at an stage.
  • A meticulous ear, nose and throat examination and thorough evaluation of nasal symptoms with associated cervical lymphadenopathy may lead to an early diagnosis of nasopharyngeal cancer's.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20329676.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


23. Zagolski O, Dwivedi RC, Subramanian S, Kazi R: Non-Hodgkin's lymphoma of the sino-nasal tract in children. J Cancer Res Ther; 2010 Jan-Mar;6(1):5-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the sino-nasal tract in children.
  • Childhood head and neck cancers are relatively uncommon.
  • Of all head and neck cancers occurring in children, non-Hodgkin's lymphoma (NHL) is the most common, others being rhabdomyosarcoma and nasopharyngeal carcinoma.
  • These can be of several different types depending on the predominant cell type and histologic appearance, the most common histological variant being diffuse large B-cell lymphoma.
  • In an attempt to simplify the classification and to develop a universally acceptable classification and staging, they have been classified and staged numerous times over the last three decades, adding more confusion to the topic.
  • Clinical presentations vary according to the histological type.
  • The low grade lymphomas present with a nasal cavity or para-nasal sinus mass associated with obstructive symptoms and/or lymphadenopathy, while high grade lymphomas present with aggressive signs and symptoms including non-healing ulcer, epistaxis, septal perforation and bony destruction.
  • The primary treatment consists of chemotherapy and / or radiation therapy, which is able to achieve remission in two-third of the patients, however, prognosis remains poor with cumulative five-year survival rates at about 30% for all the types of sino-nasal NHLs.
  • Newer targeted therapy (monoclonal antibodies) and combination therapies (including stem cells) are currently being tested in order to improve survival rates in these patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Nose Neoplasms / pathology. Paranasal Sinus Diseases / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Humans. Neoplasm Staging. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479539.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


24. Price DL, Wong RJ, Randolph GW: Invasive thyroid cancer: management of the trachea and esophagus. Otolaryngol Clin North Am; 2008 Dec;41(6):1155-68, ix-x
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive thyroid cancer: management of the trachea and esophagus.
  • Well-differentiated thyroid cancer most commonly presents as an intrathyroidal tumor; however, extrathyroidal extension occurs in approximately 6% to 13% of patients and carries a significant negative impact on survival.
  • Adjuvant postoperative therapies for thyroid cancers with extrathyroidal extension include thyroid hormone suppression, radioactive iodine therapy, and external beam radiotherapy.
  • This summary reviews approaches to the management of invasive thyroid cancers involving the aerodigestive tract.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1997 Jul;226(1):85-91 [9242342.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Jul;114(1):84-92 [9240297.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):375-88 [9445196.001]
  • [Cites] Thyroid. 1998 Sep;8(9):737-44 [9777742.001]
  • [Cites] Eur J Radiol. 1998 Nov;29(1):4-10 [9934552.001]
  • [Cites] Am Surg. 1999 Aug;65(8):754-9; discussion 759-60 [10432086.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Nov;131(5):596-600 [15523432.001]
  • [Cites] J Thorac Cardiovasc Surg. 1964 Nov;48:741-9 [14221240.001]
  • [Cites] Radiat Med. 2004 Sep-Oct;22(5):346-53 [15553016.001]
  • [Cites] Surgery. 2004 Dec;136(6):1310-22 [15657592.001]
  • [Cites] Surgery. 2005 Mar;137(3):342-7 [15746790.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 May;134(5):819-22 [16647541.001]
  • [Cites] Surgery. 2006 Mar;139(3):357-62 [16546500.001]
  • [Cites] Surg Today. 2005;35(10):819-22 [16175461.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] Anticancer Drugs. 2006 Sep;17(8):869-79 [16940797.001]
  • [Cites] Laryngoscope. 2006 Sep;116(9):1657-61 [16954999.001]
  • [Cites] Surgery. 2006 Dec;140(6):866-72; discussion 872-3 [17188132.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 May;133(5):481-5 [17520762.001]
  • [Cites] Ann Thorac Surg. 2007 Jun;83(6):1952-9 [17532377.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2007 Apr;27(2):62-7 [17608132.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):58-63 [17904235.001]
  • [Cites] Am J Gastroenterol. 2007 Dec;102(12):2678-9 [18042103.001]
  • [Cites] Surgery. 2007 Dec;142(6):952-8; discussion 952-8 [18063081.001]
  • [Cites] Thyroid. 1999 Oct;9(10):1017-22 [10560957.001]
  • [Cites] Clin Radiol. 2000 Mar;55(3):222-6 [10708617.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 May;122(5):763-7 [10793362.001]
  • [Cites] Surgery. 2001 Jan;129(1):23-8 [11150030.001]
  • [Cites] AJR Am J Roentgenol. 2001 Oct;177(4):929-36 [11566708.001]
  • [Cites] Trans Am Clin Climatol Assoc. 2002;113:241-60 [12053713.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1071-3 [12016485.001]
  • [Cites] Curr Drug Targets Immune Endocr Metabol Disord. 2001 Aug;1(2):103-15 [12476792.001]
  • [Cites] J Comput Assist Tomogr. 2003 Jan-Feb;27(1):18-25 [12544237.001]
  • [Cites] Ann Med. 2002;34(7-8):554-64 [12553495.001]
  • [Cites] AJR Am J Roentgenol. 2003 Mar;180(3):837-42 [12591706.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Sep;15(6):337-41 [14524487.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2004 Sep;113(9):749-53 [15453535.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1969 Apr;78(2):285-96 [5775394.001]
  • [Cites] Arch Otolaryngol. 1974 Apr;99(4):255-60 [4594223.001]
  • [Cites] Ann Thorac Surg. 1977 Aug;24(2):100-7 [327958.001]
  • [Cites] Ann Thorac Surg. 1977 Aug;24(2):99 [879905.001]
  • [Cites] Am J Surg. 1980 Oct;140(4):514-7 [7425234.001]
  • [Cites] Am J Surg. 1981 Oct;142(4):480-3 [7283051.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1984 Feb;9(1):21-5 [6723096.001]
  • [Cites] Cancer. 1985 May 1;55(9 Suppl):2062-71 [3919920.001]
  • [Cites] Ann Thorac Surg. 1986 Sep;42(3):287-98 [3753077.001]
  • [Cites] Surgery. 1986 Dec;100(6):1098-107 [3787465.001]
  • [Cites] Otolaryngol Clin North Am. 1990 Jun;23(3):495-507 [2195434.001]
  • [Cites] Laryngoscope. 1990 Aug;100(8):824-30 [2381258.001]
  • [Cites] Ann Thorac Surg. 1992 Jul;54(1):3-9; discussion 9-10 [1610250.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):658-61 [1463119.001]
  • [Cites] Head Neck. 1993 Jul-Aug;15(4):289-91 [8360048.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):866-70 [8375857.001]
  • [Cites] Head Neck. 1994 Mar-Apr;16(2):165-72 [8021137.001]
  • [Cites] Eur J Cancer. 1994;30A(6):733-9 [7917529.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):636-9 [7978010.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Dec;120(12):1377-81 [7980904.001]
  • [Cites] Ear Nose Throat J. 1994 Sep;73(9):659-62 [7988395.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Jul;113(1):42-8 [7603720.001]
  • [Cites] Am J Surg. 1995 Nov;170(5):467-70 [7485734.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):172-80 [8630926.001]
  • [Cites] Thyroid. 1997 Apr;7(2):265-71 [9133698.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 May;123(5):484-90 [9158394.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2268-72 [9404704.001]
  • (PMID = 19040976.001).
  • [ISSN] 0030-6665
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA009685-17; United States / NCI NIH HHS / CA / T32 CA009685; United States / NCI NIH HHS / CA / T32 CA009685-17
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 64
  • [Other-IDs] NLM/ NIHMS111817; NLM/ PMC2750808
  •  go-up   go-down


25. Inaji H, Komoike Y, Motomura K, Kasugai T, Sawai Y, Koizumi M, Nose T, Koyama H: Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer. Breast Cancer; 2002;9(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer.
  • Several recent trials have demonstrated that neoadjuvant chemotherapy can allow more patients to successfully undergo breast-conserving treatment (BCT), and does not confer a survival disadvantage compared with standard adjuvant chemotherapy.
  • In addition, the pathological response of primary breast tumors to neoadjuvant chemotherapy appears to be a surrogate marker for patient outcome.
  • In our series, during the period from May 1995 to December 2000, 86 patients with tumors between 3.1 and 6.0 cm in diameter received epirubicin-based neoadjuvant chemotherapy.
  • The margin positive rate was 14.1%(9/64), similar to the rate after BCT for early-stage breast cancers, the largest diameter of which was smaller than 3 cm.
  • At a median follow-up of 30 months, only 3 patients in the BCT group have developed local recurrence; the local recurrence rate appears to be comparable to that after BCT for early stage breast cancers.
  • Long term follow-up is required, however, to establish whether this procedure is a safe alternative to mastectomy for patients with large breast cancers.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Mastectomy, Segmental. Neoadjuvant Therapy
  • [MeSH-minor] Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Epirubicin / administration & dosage. Female. Humans. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12196717.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin
  • [Number-of-references] 28
  •  go-up   go-down


26. Preś K, Pośpiech L, Krecicki T, Nadolska B, Kubacka M, Zatoński T, Jabłonka A, Piechnik-Resler D, Jankowska-Konsur A: [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001]. Wiad Lek; 2006;59(11-12):797-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001].
  • Malignant neoplasms of the nose and paranasal sinuses occur rarely but due to late diagnosis and poor treatment effects still remain a serious problem.
  • The aim of the study was the analysis of all nose and paranasal sinus neoplasms treated at Lower Silesia in the years 1992-2001.
  • MATERIAL AND METHODS: In the years 1992-2001 in Lower Silesia region there were 182 patients treated for malignant nose and paranasal sinus tumors.
  • Principal management was combined therapy--surgery with radiotherapy in 84% of the cases.
  • Radiotherapy alone was performed in 8.8% and chemotherapy as palliative treatment in 7.1%.
  • CONCLUSIONS: Unsatisfactory results of treatment are an effect of a high advanced stage of the tumor while diagnosed.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Nose Neoplasms / epidemiology. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / epidemiology. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Neoplasm Staging / classification. Nose. Poland / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Sex Distribution. Survival Rate

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427494.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down






Advertisement